MedPath

Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism

Phase 1
Conditions
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Interventions
Diagnostic Test: Brain MRI
Registration Number
NCT03821571
Lead Sponsor
National Taiwan University Hospital
Brief Summary

Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone and is related to hypertension and hypokalemia. PA accounts for 3-10 % of hypertensive patients, and a higher incidence of vascular complications compared to patients with essential hypertension was observed in several studies. The vascular injury from excessive aldosterone can occur via oxidative stress and collagen remodeling, causing endothelial dysfunction and fibrosis in the vasculature.

The association between cerebral small vessel disease (cSVD) and hypertension has been well studies in the past decades. However, not much study has focused on the cSVD burden in patient with PA. The goal of this study is to understand the features of cSVD in patients with PA and for the purpose of understanding the underlying pathophysiology of cerebrovascular injury in this particular patient group.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • age between 20-90 years-old
  • patient with primary aldosteronism or healthy control
  • consciousness clear
  • willing to receive brain MRI
Read More
Exclusion Criteria
  • renal failure or Creatinine > 2mg/dl
  • coagulopathy or hepatic insufficiency
  • unstable vital sign under inotropic agents
  • pregnancy
  • metal implant or cardiac pacemaker
  • major brain surgery
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Patient with essential hypertensionBrain MRIBrain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
Patient with primary aldosteronismBrain MRIBrain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
Primary Outcome Measures
NameTimeMethod
Cerebrovascular reactivityDuring the brain MRI

Cerebrovascular reactivity measured by MRI under primary aldosteronism

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Bei-Hu Branch, National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath